Lichen Capital
VC Fund
Lichen Capital is a Private Equity Firm.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Lichen Capital invests in
Stages Lichen Capital invests in
Countries Lichen Capital invests in
Investment Focus
Industry
- Medical 5 (36%)
- Health Care 5 (36%)
- Biopharma 4 (29%)
- Biotechnology 3 (21%)
- Therapeutics 2 (14%)
Stage
- Series B 5 (36%)
- Series A 3 (21%)
- Seed 2 (14%)
- Angel 2 (14%)
- Series C 1 (7%)
Country
- China 11 (79%)
- United States 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Spurious
|
Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $35M / Seed / Jan 30, 2026 | |
Fortitude Biomedicines
|
Fortitude Biomedicines is a biotechnology company that develops antibody-based biologic drugs targeting autoimmune diseases. | $13M / Seed / Jan 26, 2026 | |
Oricell Therapeutics
|
OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices for tumor immunotherapy. | $70M / Series C / Jan 12, 2026 | |
Agile Medical
|
Agile Medical, a surgical robot company, focuses on research, development, and industrialization of intelligent surgical products. Agile Medical's technology innovation platform covers mechanics, electronics, optics, computing, and software. | Series B / Nov 03, 2025 | |
|
Spurious
|
Sipurui is a pharmaceutical company specializing in the development of small molecule anti-tumor drugs, with a particular emphasis on iterative innovation to enhance the efficacy and selectivity of cancer therapies. | $27.8M / Angel / Jun 04, 2025 | |
Bivision
|
Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment. | $13.8M / Series A / Jul 26, 2024 | |
Scitech pharma
|
Scitech pharma is a small molecule drug developer using AI-driven technology for large-scale drug design and screening. They focus on tumors, autoimmune systems, and central nervous system, providing optimal solutions for patients. | $13.8M / Series A / Apr 26, 2024 | |
Curegene
|
Curegene focuses on the treatment of anti-viral diseases as well as cardiovascular and cerebrovascular diseases. The company has made strides in the development of small molecules and nucleic acid pharmaceuticals and currently possesses the most advanced targeted prodrug and nucleic acid drug technology platforms. | $14.1M / Series B / Jan 31, 2024 | |
Seamaty
|
Seamaty is committed to the exploration, manufacturing, and marketing of reagents and equipment for point-of-care testing (POCT). | Venture - Series Unknown / Dec 15, 2023 | |
Angitia Biopharmaceuticals
|
Angitia Biopharmaceuticals is a global biotechnology company focusing on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. | $46M / Series B / Oct 19, 2023 | |
| See all 14 investments → | |||
Co-Investors
OrbiMed
3 deals together
Gaorong Capital
2 deals together
BioTrack Capital
2 deals together
LongRiver Investments
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lichen Capital invest in?
Lichen Capital invests primarily in Medical, Health Care and Biopharma startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Lichen Capital last invest?
The most recent investment recorded for Lichen Capital closed in Jan 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
